« Back to News

BIOMARK GRANTS OPTIONS

March 2, 2021

Vancouver, British Columbia – (March 2, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has granted 2,100,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to third-party consultants to support market communication and corporate strategy as it advances its commercialization efforts. Each option is exercisable into one common share at a price of $0.25 per share and will vest immediately. The options will expire two years from the date of grant. All other terms and conditions of options are in accordance with the terms of the Company’s Stock Option Plan.

In addition, BioMark has cancelled 100,000 options previously issued to consultants.

Press Release – BioMark Grants Options